[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"parkinson-s-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:parkinson-s-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,82,109,130,153,202,225,253,281],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100641553","cognitive-based-balance-rehabilitation-in-parkinsons-disease-virtual-reality-vs-dual-task-100641553",false,"NCT07660978","Cognitive-Based Balance Rehabilitation in Parkinson's Disease: Virtual Reality vs. Dual Task","Effects of Cognitive-Based Balance Rehabilitation on Balance, Gait and Cognitive Functions in Parkinson's Disease Patients: Comparison of Virtual Reality and Dual Task","Inclusion Criteria:\n\n* Diagnosed with Parkinson's Disease by a neurologist.\n* Hoehn \\& Yahr Stage I-III.\n* Aged between 40-80 years.\n* Literate and capable of performing basic mathematical calculations.\n* Montreal Cognitive Assessment≥21\n* Stable pharmacological treatment.\n* Physician's approval for exercise participation.\n\nExclusion Criteria:\n\n* Currently participating in another exercise or drug trial.\n* Presence of any additional neurological disorders.\n* Significant musculoskeletal disorders, arthritis, or cardiovascular disease.\n* Uncontrolled epilepsy or severe orthostatic hypotension.\n* Engaged in regular moderate-intensity exercise more than once a week in the last 6 months.","ALL","40 Years","80 Years",{"count":20,"type":21},34,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, randomized, single-blind, controlled clinical trial aims to evaluate and compare the efficacy of cognitive-based balance rehabilitation delivered via immersive Virtual Reality (VR) versus traditional Dual-Task Training (DTT) on balance, gait, cognitive functions, and quality of life in patients with Parkinson's Disease (PD). Postural instability and cognitive decline are hallmark features of progressive PD that significantly elevate fall risks and compromise daily independence, yet conventional pharmacological therapies offer limited effectiveness in restoring complex postural control. Given that motor and cognitive processes are intrinsically linked, this study addresses a critical gap in neurorehabilitation by investigating two contemporary modalities designed to challenge these systems simultaneously. A total of 34 participants diagnosed with PD (aged 40-80 years, Hoehn and Yahr stages I-III) will be randomly allocated to either the Dual-Task Group (DTG), receiving structured therapeutic exercises integrated with sequential cognitive tasks, or the Virtual Reality Group (VRG), engaging in an immersive balance program utilizing the Oculus Quest 2® headset with the FIT-XR application. Both groups will undergo an identical intervention protocol consisting of 45-minute supervised sessions, conducted twice weekly for 8 consecutive weeks during their pharmacological \"on\" phase. Standardized assessments will be performed by a blinded clinician at baseline and post-intervention (Week 8). The primary outcome measures will be dynamic balance and gait assessed through the Mini-Balance Evaluations Systems Test (Mini-BESTest) alongside global cognitive performance measured via the Montreal Cognitive Assessment (MoCA). Secondary outcomes will encompass objective posturographic indices using the Biodex Balance System, motor severity via the Unified Parkinson's Disease Rating Scale (UPDRS-III), freezing of gait, health-related quality of life, global perceived improvement, and potential cyber-sickness symptoms monitored through the Virtual Reality Sickness Questionnaire (VRSQ) to comprehensively determine the safety and comparative therapeutic value of these interventions.",[27,28,29,30,31,32,33],"PARKINSON DISEASE (Disorder)","Parkinson Disease (PD)","Parkinson s Disease","Postural Instability","Postural Instability Gait Disorders","Gait Disorders","Cognitive Dysfunction, Cognitive Disorder",[35,30,32,36,37,38],"Parkinson Disease","Cognitive Dysfunction","Dual Task","Virtual Reality","NOT_YET_RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":21},"2026-06-20",{"date":47,"type":21},"2027-12-30",{"name":49,"class":50},"Bezmialem Vakif University","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100635603","effects-of-accelerated-rtms-on-motor-and-cognitive-function-in-parkinsons-disease-100635603","NCT07554833","Effects of Accelerated rTMS On Motor and Cognitive Function in Parkinson's Disease","Clinical Effects of Accelerated rTMS Targeting Motor Cortex on Motor and Cognitive Function in Parkinson's Disease: A Prospective Pilot Study","Inclusion Criteria:\n\n* Subject must be 50 to 90 years of age, inclusive, on the day of signing informed consent.\n* Diagnosis of idiopathic Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria or UK Parkinson's Disease Society Brain Bank criteria.\n* Hoehn and Yahr stage 1-3 (mild to moderate disease severity).\n* MDS-UPDRS-III (Motor Examination) score ≥10 at screening.\n* Stable doses of anti-parkinsonian medications (including levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, amantadine) for at least 4 weeks prior to screening, with no anticipated changes during the study period.\n* Ability to provide written informed consent.\n* Subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.\n* Sufficient visual and auditory acuity to complete motor and cognitive assessments.\n* Availability and willingness to complete all scheduled study visits.\n* Presence of a reliable study partner or caregiver who can provide information about the participant's motor, cognitive, and functional status.\n* Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the contralateral hand muscles.\n* Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in motor or cognitive function, including non-invasive brain stimulation treatments other than the study procedure during study participation.\n* Subjects willing and able to maintain their regular (pre-procedure) medication regimen, diet, and exercise routine without affecting significant change in either direction during study participation.\n* Willingness to comply with study instructions and to return to the clinic for the required visits.\n* Women of child-bearing potential are required to use birth control measures during the whole duration of the study.\n\nExclusion Criteria:\n\n* Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators.\n* Metallic, ferromagnetic, or other magnetic-sensitive implants\u002Fobjects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic, or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 inches (30 cm) of the therapy coil. Examples include implanted electrodes\u002Fstimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes, and tattoos with metallic ink.\n* Drug pumps within 12 inches (30 cm) of the therapy coil.\n* Inability to determine the motor threshold of the participant (i.e., the minimum stimulus required to induce contraction of the contralateral hand muscles cannot be established).\n* History of seizure disorder or epilepsy, except for a single remote seizure more than 5 years ago, which may be permitted at investigator discretion.\n* Elevated risk of seizure due to traumatic brain injury with loss of consciousness \\>30 minutes within the past 12 months.\n* Current use of medications known to significantly lower seizure threshold (e.g., clozapine, bupropion at doses \\>450 mg\u002Fday, theophylline, high-dose tricyclic antidepressants) or recent dose reduction of anticonvulsant medications or benzodiazepines within 4 weeks of screening.\n* Atypical parkinsonism or Parkinson-plus syndromes (e.g., progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration).\n* Hoehn and Yahr stage 4 or 5 (severe disease with significant disability).\n* Severe dementia, defined as MoCA score below 10, or inability to follow simple verbal commands or complete basic motor and cognitive assessments.\n* Rapidly progressive cognitive decline or suspected prion disease, autoimmune encephalitis.\n* Brain tumor, intracranial hemorrhage within the past 12 months, arteriovenous malformation, or increased intracranial pressure.\n* Acute stroke within the past 3 months.\n* Prior deep brain stimulation (DBS) surgery or other neurosurgical procedures for Parkinson's disease.\n* Has a current diagnosis of psychotic disorder, bipolar disorder, or other psychiatric condition that, in the investigator's opinion, would interfere with the subject's ability to participate in the trial.\n* Has a current or recent history of serious suicidal ideation within the past 6 months, corresponding to a positive response on item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS, or a history of suicidal behavior within the past year, as validated by the C-SSRS at screening.\n* History of substance or alcohol use disorder of moderate to severe severity according to DSM-5 criteria within 6 months before screening, or positive test result(s) for drugs of abuse (including opiates, cocaine, cannabinoids, methamphetamines, amphetamines) at screening.\n* Has history of or current clinically significant and\u002For unstable medical condition that could interfere with study participation or pose safety concerns, including but not limited to: Moderate or severe hepatic impairment (Child-Pugh Score ≥7); Severe renal impairment (estimated creatinine clearance below 30 mL\u002Fmin or serum creatinine \\>2 mg\u002FdL); Unstable cardiac, vascular, or pulmonary disease Note: Subjects with chronic but stable, well-controlled conditions may be allowed in the study upon agreement with the investigator.\n* Has uncontrolled hypertension (systolic blood pressure \\>160 mm Hg or diastolic blood pressure \\>100 mm Hg, despite diet, exercise, or a stable dose of antihypertensive therapy) at screening.\n* Has clinically significant ECG abnormalities at screening, defined as: QTc interval (Fridericia's formula): ≥450 msec (males); ≥470 msec (females); Evidence of 2nd or 3rd degree atrioventricular block, or 1st degree atrioventricular block with PR interval \\>210 msec; Left bundle branch block; Features of new ischemia; Other clinically important arrhythmia\n* Has a known malignancy or history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that, in the opinion of the investigator, is considered cured with minimal risk of recurrence).\n* Had clinically significant acute illness within 7 days prior to study rTMS treatment.\n* Had major surgery (e.g., requiring general anesthesia) within 2 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Note: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.\n* Is pregnant or breastfeeding while enrolled in this study or within 1 month after the last session of study rTMS treatment.\n* Has received an investigational drug or used an invasive investigational medical device within 3 months before screening, or is currently enrolled in an investigational study.\n* Prior treatment with rTMS within 6 months of screening.\n* Subjects willing to partake in any treatments other than the study procedure for the improvement in cognitive function, including non-invasive brain stimulation treatments other than the study procedure, during study participation.\n* Has psychological and\u002For emotional problems which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements.\n* Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.\n* Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.","50 Years","90 Years",{"count":61,"type":21},40,[24],"Parkinson's disease (PD) is a brain disorder that causes progressive problems with movement, such as slowness, stiffness, tremor, and difficulty walking. Many people with PD also develop problems with thinking and memory. Current medications can help control movement symptoms but often become less effective over time and may cause side effects. There is a need for additional treatment options that can address both movement and thinking difficulties in PD.\n\nRepetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment that uses magnetic pulses delivered to the scalp to stimulate specific areas of the brain. Previous research has shown that rTMS targeting the motor cortex (the part of the brain that controls movement) can improve motor symptoms in people with PD.\n\nThe purpose of this pilot study is to evaluate whether an accelerated course of rTMS targeting the motor cortex can improve movement and thinking abilities in people with mild to moderate Parkinson's disease. The study will enroll 40 participants aged 50 to 90 years at the San Francisco Neurology and Sleep Center.\n\nParticipants will receive 6 sessions of rTMS using the EXOMIND™ device, administered twice per week over approximately 3 weeks. Each session delivers high-frequency magnetic stimulation to the motor cortex on both sides of the brain. Participants will be assessed before treatment, at the last treatment session, and at 1-month and 3-month follow-up visits.\n\nThe primary outcome measure is the change in motor symptoms as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS-III) at 1 month after treatment. Secondary outcomes include additional measures of walking and gait, domain-specific cognitive testing using the Creyos cognitive battery (assessing memory, attention, reasoning, and other thinking skills), the Montreal Cognitive Assessment (MoCA), depression symptoms (PHQ-9), and quality of life (PDQ-39).\n\nThis is a single-center, open-label study with no placebo or control group. Total participation duration is up to 139 days, including screening, treatment, and follow-up visits.",[27,29],[66,67,68,69,70],"rTMS","ExoMind","Parkinson's Disease","PD","Cognitive Function","RECRUITING","2026-06-12",{"date":74,"type":43},"2026-06-16",{"date":76,"type":21},"2026-06-03",{"date":78,"type":21},"2027-12-31",{"name":80,"class":50},"San Francisco Neurology and Sleep Center",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100616937","phase-2-d-spark-a-clinical-trial-of-d-serine-for-modifying-parkinsons-disease-progression-100616937","NCT07312110","D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression","D-SPARK: A Randomized Double Blind Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression","D-SPARK","Inclusion Criteria:\n\n* A clinical diagnosis of PD\\* according to the clinically established MDS clinical diagnostic criteria for Parkinson's disease within 5 years.\n* \\[¹²³I\\]FP-CIT single photon emission CT (DaTscan) confirming dopaminergic nigrostriatal denervation.\n* Hoehn and Yahr score \\\u003C 3 at enrollment.\n* Optimal symptomatic PD treatment, not requiring adjustments, for at least 2 weeks.\n* Age ≥40 and ≤ 80 years at time of enrollment.\n\nExclusion Criteria:\n\n* Dementia or neurodegenerative disorder other than PD at baseline visit.\n* Atypical parkinsonism (PSP, MSA, CBD vascular parkinsonism, or drug induced parkinsonism).\n* Any known monogenic cause of PD (GBA1 variation is accepted).\n* Any psychiatric disorder that would interfere with compliance in the study.\n* Any severe somatic illness that would make the individual unable to comply and participate in the study.\n* Use of D-serine supplementation within 90 days of enrolment.\n* Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit.\n* Active of planned pregnancy during trial period.\n* Cognitive impairment as measured by the Mini Mental Status Exam MMSE) \\\u003C 20.\n* Weight \\\u003C 45 kg.\n* Urinary albumin\u002Fcreatinine ratio ≥ 20 mg\u002Fmmol at time of enrollment.\n* Participants will be excluded if they have CKD stage 3 or higher, defined as:\n\n  * Estimated golumerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73min\\^2 at screening, calculated using the CKD-EPI 2021 creatinine equation.",{"count":91,"type":21},100,[93],"PHASE2","This clinical study, designed as a randomized, double-blind, placebo-controlled trial, aims to investigate if modulation of the N-methyl-D-aspartate receptor (NMDAR) via its co-agonist D-serine has therapeutic benefits in Parkinson's disease (PD). All patients will receive both placebo and D-serine over different time periods during the study.\n\nPreclinical studies have shown that blocking glycine transporters, which elevates endogenous glycine levels, can restore NMDAR function and improve motor deficits in PD models. A clinical trial demonstrated that oral D-serine (30 mg\u002Fkg\u002Fday for 6 weeks) significantly reduced extrapyramidal and abnormal involuntary movements in PD patients compared to placebo, with improvements observed in both motor and non-motor symptoms. D-serine supplementation has shown an acceptable safety profile with doses up to 120 mg\u002Fkg showing no significant adverse effects in clinical studies.\n\nThe D-SPARK trial primarily aims to determine the efficacy of D-serine supplementation on clinical severity of PD as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).\n\nSecondary aims are to determine the efficacy of D-serine supplementation on improving dopaminergic nigrostriatal innervation as measured by single-photon emission tomography (SPECT) based imaging of the dopamine transporter (DaT-scan) and cognition as measured by the California Verbal Learning Test version 2 (CLVT-II).\n\nThe study will include 100 persons with Parkinson's disease (PwPD) diagnosed no longer than 5 years before baseline. Participants will be randomly assigned to receive D-Serine 4000 mg daily or placebo for defined periods of time during a 58 week treatment period, followed by a 12 week washout period.\n\nParticipants will undergo:\n\n* Clinical evaluations, including clinical rating scales and questionnaires.\n* Cognitive assessments.\n* Bio sampling of whole blood and blood plasma.\n* Single-photon emission tomography (SPECT) imaging of dopamine transporter levels (DaT-scan)\n\nThe outcomes of this study could potentially demonstrate that D-serine reduces symptom severity in Parkinson's disease and\u002For has an impact on the clinical trajectory of Parkinson's disease, benefiting persons living with Parkinson's disease, their families and society as a whole.",[29,28],[97,98,99],"Serine","Parkinsons disease","D-serine",{"date":101,"type":43},"2026-06-04",{"date":103,"type":43},"2026-01-20",{"date":105,"type":21},"2028-12",{"name":107,"class":50},"Haukeland University Hospital",11,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":128,"locationsCount":81},"100638315","trunk-control-exercises-and-mirror-therapy-on-balance-and-posture-in-parkinsons-disease-100638315","NCT07610031","Trunk Control Exercises and Mirror Therapy on Balance and Posture in Parkinson's Disease","Effects of Trunk Control Exercises and Mirror Therapy on Balance and Posture in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* • 50-70 age(Bomasang-Layno et al., 2015)\n\n  * Both genders (Bomasang-Layno et al., 2015)\n  * Patient with grade 1,2,3 Parkinsonism (according to Hoehn and Yahr scale)\n  * Patient taking fixed dose of medicines\n  * No cognitive impairment (according to Mini-Mental scale 24-30 scoring) (Capecci et al., 2014)\n  * The patient was able to get out of chairs and beds without assistance (Hoffmann et al., 2016).\n  * Individuals without significant dyskinesias or \"on-off\" periods.(Lötzke et al., 2015)\n\nExclusion Criteria:\n\n* • Patient having any recent episode of epilepsy(Bomasang-Layno et al., 2015)\n\n  * Patient has had any recent trauma. (Hong et al., 2009)\n  * Individuals free from chronic diseases such as unstable cardiovascular disease that could compromise their safety during training or testing (Hoffmann et al., 2016).","70 Years",{"count":118,"type":21},36,[24],"Parkinson's disease (PD) is movement disorder of the nervous system that worsens over time. As nerve cells (neurons) in parts of the brain weaken or are damaged or die, people may begin to notice problems with movement, tremor, stiffness in the limbs or the trunk of the body, or impaired balance. As these symptoms become more obvious, people may have difficulty walking, talking, or completing other simple tasks. Not everyone with one or more of these symptoms has PD, as the symptoms appear in other diseases as well.\n\nBoth non-modifiable (age, gender) and modifiable risk factors such as occupation, exposure to pesticides, and depression have an association with PD. Several studies have suggested that Parkinson disease is more common in men. The MT mechanism is based on the concept of visual illusion. The movement of the non-paretic part in front of the mirror (reflective side) is perceived as that of the paretic body part (hidden beside the mirror). MT allows an individual to have an experience of normal movement, even for the severely paralyzed limb. In addition, wherever other rehabilitation methods fail to induce normal movements without any compensation, MT may act as a foundation step for further motor therapy. The perception of movement illusion, a neuropsychological phenomenon may induce neural activation of the lesioned brain and enhance associated motor recovery. Therefore the aim of this study is to compare the effects of truck control exercise program and mirror therapy on balance and postural instability in patients with Parkinson's disease.",[29],"2026-05-21",{"date":124,"type":43},"2026-05-27",{"date":126,"type":43},"2024-12-22",{"date":45,"type":21},{"name":129,"class":50},"University of Lahore",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":81},"100636993","the-efficacy-and-safety-of-temporal-interference-stimulation-on-motor-symptoms-of-parkinsons-disease-100636993","NCT07572903","The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease","The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease: A Three-arm, Randomized, Double-blind, Parallel-controlled Study","Inclusion Criteria:\n\n1. Age \\>= 40 years;\n2. Meet the diagnostic criteria for primary Parkinson's disease (MDS Parkinson's Disease Diagnostic Criteria (2015 Edition));\n3. No medication adjustment in the 4 weeks before and during each stimulation;\n4. MDS-UPDRS III score \\>= 8 points, Hoehn-Yahr score 1-4 points\n\nExclusion Criteria:\n\n1. Focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or above) on previous head MRI\u002FCT scans;\n2. Various secondary Parkinson's syndromes (vascular Parkinson's syndrome, drug-induced Parkinson's syndrome, etc.);\n3. Severe craniocerebral trauma, cranial surgery or deep brain stimulation treatment;\n4. Ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc.;\n5. A history of epilepsy, unexplained loss of consciousness, or taking anticonvulsant drugs for epileptic seizures;\n6. Diagnosed with neuropsychiatric diseases other than Parkinson's disease;\n7. A history of drug abuse or drug use;\n8. Participated in any clinical trial in the past 3 months;\n9. Pregnant\u002Flactating women or subjects (including men) who plan to have children within 6 months;\n10. Other situations that the researchers consider unsuitable for inclusion.",{"count":138,"type":21},90,[24],"This study aimed to observe the clinical efficacy and safety of single-target transcranial temporal stimulation (tTIS) intervention in Parkinson's disease (PD) patients and explore the neurophysiological mechanism of TIS intervention. The study was designed as a three-arm (A: GPi group, B: STN group, C: Sham group), randomized, double-blind, parallel-controlled trial. PD patients in the drug-off state (≥12 hours after drug withdrawal) were randomly assigned to receive either tTIS or sham stimulation targeting GPi\u002FSTN, with each stimulation lasting 30 minutes. Clinical symptom assessments were conducted before and after the intervention, and safety was monitored by researchers throughout the process.",[29],[29,143],"Temporal Interference Stimulation","2026-05-07",{"date":146,"type":43},"2026-05-12",{"date":148,"type":43},"2026-05-06",{"date":150,"type":21},"2026-08-01",{"name":152,"class":50},"The First Affiliated Hospital of Anhui Medical University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":16,"minAge":161,"maxAge":59,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":176,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":81},"100632087","ultra-high-resolution-pet-in-aging-neurodegeneration-and-psychotic-disorders-100632087","NCT07509125","Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders","Ultra-High Resolution PET of the Human Brain and Spinal Cord in Healthy Aging, Dementia, Movement Disorders, ALS and Psychotic Disorders","Inclusion Criteria:\n\n* WP1: Healthy controls\n* Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years);\n* Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests;\n* No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* In subjects \\\u003C 60 years of age, a normal structural MRI scan as assessed by expert radiologist.\n* In subjects \\>= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score \\\u003C= 2 (of 3) on the Age-Related White Matter changes scale are acceptable;\n* When older than 50 years of age, the volunteer is willing to undergo a p- tau217 blood sample.\n* WP2: Dementia\n* Patient has a clinical diagnosis of biomarker-proven prodromal AD\n* WP3: ALS spectrum\n* Subject must meet El Escorial Criteria (30) and Awaji-Shima criteria (31) for at least possible ALS;\n* WP4: Movement disorders\n* (all): Patient (or legal representative, when applicable) is able to understand the patient information form and give written informed consent.\n* Parkinson´s disease (PD):\n* Patient has clinically established PD based on the Movement Disorder Society (MDS) diagnostic criteria (32);\n* Patient has an abnormal 18F-PE2I PET;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline.\n* Multiple system atrophy (MSA)\n* Patient has clinically established or clinically probable MSA-P based on the\n* Movement Disorder Society (MDS) diagnostic criteria (33);\n* Patient has an abnormal 18F-PE2I PET.\n* Progressive supranuclear palsy (PSP)\n* Patient has an abnormal 18F-PE2I PET;\n* Patient has clinically established probable PSP according to the latest MDS criteria\n* Dementia with Lewy bodies (DLB)\n* Patient has probable DLB by consensus criteria (cognitive impairment MoCA \\\u003C 26 + visual hallucinations and\u002For fluctuating alertness);\n* Patient has an abnormal 18F-PE2I PET.\n* Idiopathic REM sleep behavior disorder (iRBD)\n* Patient has Polysomnography-confirmed iRBD;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* No clinical evidence of parkinsonism at baseline.\n* WP5: Psychosis\n* DSM 5 criteria for a non-affective schizophrenia spectrum psychotic disorder;\n* Age between 18 and 55 years old for adult-onset psychosis, onset of psychosis (and age) above 60 years old for very late onset psychosis.\n\nExclusion Criteria:\n\n* Subject has a history of any major (other) internal, psychiatric or neurological disease that may interfere with the investigations (especially liver and kidney disease, uncontrolled diabetes, cancer, severe depression, stroke, severe TBI);\n* Subject is currently a user (including recreational use) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse;\n* Subject chronically uses medication that has central nervous system effects (e.g. strong painkillers such as opioids, neuroleptics,..; ) (other than prescribed for the illness in case of patients);\n* Subject has had exposure to ionizing radiation (\\> 1 mSv) in other research studies within the last 12 months;\n* Subject has a contra-indication for MRI scanning;\n* Subject suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures; subject cannot lie still for (at least) 60 minutes inside the scanner;\n* (For subjects with arterial sampling): The subject is hypersensitive to lidocaine (used for local anaesthesia during the placement of the arterial catheter), has an abnormal Allen test (a test to check blood flow in the arteries of the forearm) or is on anti-coagulant therapy;\n* Subject (or his\u002Fher legal representative) does not understand the study procedures;\n* Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator;\n* Subject is potentially pregnant (hCG test can be done if doubt exists).",true,"18 Years",{"count":163,"type":21},300,[24],"The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD), Parkinson's disease and related movement disorders, amyotrophic lateral sclerosis (ALS), and psychotic disorders. Researchers will use the NeuroExplorer PET\u002FCT system, a new scanner that can show very small structures in the brain and spinal cord in much more detail than regular PET.\n\nThe main questions this study aims to answer are:\n\n* How do small but important brain regions (like the locus coeruleus, substantia nigra, and thalamic nuclei) change in healthy aging?\n* What early brain changes occur in neurodegenerative and psychotic disorders, and can they help improve early diagnosis?\n\nParticipants will:\n\n* Undergo PET and MRI brain scans using different tracers that measure brain metabolism (18F-FDG), synaptic density (¹⁸F-SynVesT-1), dopamine transporters (¹⁸F-PE2I), and tau protein buildup (¹⁸F-MK6240).\n* Complete cognitive and clinical assessments related to memory, mood, and motor or psychiatric symptoms, depending on their group.\n\nThis study will include healthy volunteers and patients with mild cognitive impairment due to Alzheimer´s disease, ALS, Parkinson's disease and related disorders, or psychotic disorders.\n\nThe results will help create detailed brain imaging maps for healthy aging and identify early biomarkers for different diseases to support better diagnosis and treatment in the future.",[167,168,29,169,170,171,172,173,174,175],"Alzheimer Dementia (AD)","ALS - Amyotrophic Lateral Sclerosis","REM Sleep Behavior Disorder (iRBD)","PSP - Progressive Supranuclear Palsy","MSA - Multiple System Atrophy","Dementia With Lewy Bodies (DLB)","ALS With Frontotemporal Dementia (ALS\u002FFTD)","Adult Onset Psychotic Disorder","Very Late Onset Psychotic Disorder",[177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192],"PET\u002FCT scan","Alzheimer´s disease","Dementia","Amyotrophic Lateral Sclerosis","Parkinson´s disease","REM sleep behavior disorders","Progressive supranuclear palsy","Multiple System Atrophy","Dementia with Lewy Bodies","Psychotic disorders","Schizophrenia","ALS with frontotemporal dementia","UHR PET","Locus coeruleus","Papez circuit","Thalamic subnuclei","2026-03-27",{"date":195,"type":43},"2026-04-03",{"date":197,"type":43},"2026-02-13",{"date":199,"type":21},"2029-09",{"name":201,"class":50},"Universitaire Ziekenhuizen KU Leuven",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":212,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":81},"100609628","colonic-tissue-biopsy-detection-of-phosphorylated-alpha-synuclein-for-parkinsons-diagnosis-or-rem-sleep-behavior-disorder-100609628","NCT07217054","Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder","Detection of Phosphorylated Alpha-Synuclein in Colonic Tissue Biopsy During Routine Colonoscopy","Syn-G","Inclusion Criteria:\n\n1. Relatively healthy men and women ≥40-99 years of age\n2. Patients with a diagnosis of\n\n   1. Clinically confirmed PD or\n   2. Clinically confirmed RBD with no diagnosis of PD, DLB or MSA\n3. Patients must have agreed to undergo a routine colonoscopy as part of their screening or surveillance for colon cancer or for diagnostic purposes for the exclusion of other GI diseases\n\nExclusion Criteria:\n\n1. Use of anticoagulants (Plavix or aspirin alone is allowed)\n2. Under active treatment for colon cancer; 30-day post anti-cancer treatment allowed\n3. Current, ongoing gastrointestinal illness\n4. Recent intrabdominal surgery\n5. Pregnant or planning to become pregnant before the scheduled colonoscopy\n6. Significant cognitive impairment, as determined by study investigators","99 Years",{"count":61,"type":21},"OBSERVATIONAL","The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease or REM Sleep Behavior Disorder (RBD). The main question it aims to answer is:\n\nCan doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease and RBD?\n\nCurrently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems and RBD by loss of muscle atonia during REM sleep, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.",[27,215,29,35],"Parkinson","2026-02-09",{"date":218,"type":43},"2026-02-11",{"date":220,"type":43},"2025-11-04",{"date":222,"type":21},"2029-10",{"name":224,"class":50},"CND Life Sciences",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":232,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":81},"100622061","rhythmic-auditory-stimulaton-using-personalized-music-therapy-in-parkinsons-disease-100622061","NCT07378722","Rhythmic Auditory Stimulaton Using Personalized Music Therapy in Parkinson's Disease","RASP-PD","Inclusion Criteria:\n\n* According to the Queen Square Brain Bank standard , clinical diagnosed patients of PD Both male and females ages 45-55 The mini mental state examination scale MMSE screening without severe cognitive impairment,can cooperate with this study \\> 23 Mild bergs balance scale BBS score (21-40 ) score\n\nExclusion Criteria:\n\n* A history of neoplasms; severe cardiovascular, respiratory, visual, auditory, andmuscular-skeletal disease; other neurological conditions; and neurologic music therapy inthelast3 months.\n\nOther disorders that could potentially influence balance and walking.","45 Years","55 Years",{"count":235,"type":21},50,[24],"Parkinson's disease (PD) is a progressive neurodegenerative disorder commonly associated with gait disturbances, balance impairments, and freezing of gait, which significantly increase the risk of falls and reduce functional independence. Conventional physical therapy improves mobility in individuals with PD; however, persistent gait deficits often remain. Rhythmic Auditory Stimulation (RAS) is an emerging, evidence-based intervention that uses external auditory cues to enhance gait timing, stride length, and movement initiation.\n\nThis randomized controlled trial aims to evaluate the effectiveness of rhythmic auditory stimulation using personalized music therapy combined with conventional physical therapy compared to conventional physical therapy alone in individuals with Parkinson's disease. The primary outcomes include freezing of gait, gait velocity, and balance performance. Forty-two clinically diagnosed Parkinson's disease patients will be randomly allocated into two groups. Group A will receive conventional physical therapy, while Group B will receive rhythmic auditory stimulation using personalized music in addition to conventional therapy over an 8-week intervention period.\n\nThe findings of this study may provide clinical evidence supporting the integration of personalized rhythmic auditory stimulation into rehabilitation programs for improving gait and balance in individuals with Parkinson's disease.",[29],[240,241,242,243],"Parkinson's disease","Rhythmic auditory stimulation","Personalized music therapy","Freezing of gait","2026-01-23",{"date":246,"type":43},"2026-01-30",{"date":248,"type":21},"2026-02-05",{"date":250,"type":21},"2026-04-06",{"name":252,"class":50},"Rumesa Butt",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":18,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":81},"100614832","mrgfus-for-parkinsons-tremor-100614832","NCT07284719","MRgFUS for Parkinson's Tremor","Predictors and Mechanisms of Tremor Relapse After MR-Guided Focused Ultrasound Thalamotomy in Parkinson's Disease","Inclusion Criteria:\n\n* Established diagnosis of idiopathic Parkinson's disease\n* Tremor not manageable with optimal medication\n* Clinical Indication for MRgFUSth\n* Able to understand study requirements and provide consent\n* HOEHN and YAHR \\\u003C3\n\nExclusion Criteria:\n\n* Dementia or severe cognitive impairment\n* The presence of another significant neurological\u002Fpsychiatric disorder or significant disease\n* Severe psychopathology, not medically managed\n* Poor balance and gait function based on neurological examination\n* Epilepsy\n* Active drug abuse\n* History of stroke or structural lesions on MRI that could interfere with image analysis.\n* Contraindications for MRI\n* Cardiac pacemaker\n* Pregnancy or breast-feeding\n* Claustrophobia\n* Patients unable to lie on the back for 2-4 hours in the MR-scanner-setting\n* Patients who do not want information about findings of unknown disease during the trial\n* SDR (Skull density rate) lower than 0.35",{"count":261,"type":21},20,[24],"This study investigates magnetic resonance-guided focused ultrasound thalamotomy (MRgFUSth) for people with Parkinson's disease (PD) and tremor not responding to conventional standard doses of dopamine replacement therapy. The aim is to identify clinical and imaging biomarkers predictive of sustained tremor control up to 24 months after MRgFUSth treatment. Participants will undergo a suprathreshold levodopa test and ¹⁸F-DOPA PET imaging to evaluate dopaminergic and serotonergic involvement in tremor. All participants will receive MRgFUSth and be followed for 24 months with standardized clinical, cognitive, and quality-of-life assessments. The study seeks to improve understanding the possible mechanisms of tremor relapse and inform patient selection for MRgFUSth in PD.",[29,265],"Tremor",[267,268,240,269,270,271],"MRgFUS","MR-guided focused ultrasound","tremor","Parkinson's tremor","Relapse","2026-01-05",{"date":274,"type":43},"2026-01-07",{"date":276,"type":43},"2025-12-01",{"date":278,"type":21},"2029-02",{"name":280,"class":50},"Aarhus University Hospital",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":287,"targetDuration":4,"studyType":212,"phases":4,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":81},"100604375","which-tools-better-predict-fall-risk-in-parkinsons-disease-a-comparative-study-of-objective-self-reported-and-functional-balance-assessment-100604375","NCT07148700","Which Tools Better Predict Fall Risk in Parkinson's Disease: A Comparative Study of Objective, Self-Reported, and Functional Balance Assessment","Inclusion Criteria:\n\n* Age between 40 and 80 years old\n* Receiving stable dopaminergic treatment\n* No other neurological disorders besides PD\n* A Standardized Mini-Mental State Examination (MMSE) score \\>24\n* Hoehn and Yahr stage between 1-3\n* Voluntarily agreed to participate in the study after receiving detailed information\n\nExclusion Criteria:\n\nPresence of visual, hearing impairments, cardiovascular or pulmonary diseases that could affect study outcomes\n\n* Having mental or physical impairments severe enough to hinder communication\n* Clinically unstable condition within the past month\n* Participation in a rehabilitation program within the last six months",{"count":61,"type":21},"Introduction: Falls are common in Parkinson's disease (PD), affecting 30-90% of patients annually, with more than half experiencing recurrent falls. Identifying balance assessment tools that are both practical and predictive of fall risk is therefore essential. This study aimed to investigate the relationship between fall frequency and three balance assessment tools: the Biodex Balance System (objective), the Falls Efficacy Scale-International (FES-I) (self-reported), and the Mini-Balance Evaluation Systems Test (Mini-BESTest) (functional).\n\nMethods: Patients with PD at Hoehn and Yahr stages 1-3 will be included in the study. Fall data will be collected using a fall diary, while objective balance will be assessed with the Biodex Balance System, functional performance will be evaluated with the Mini-BESTest, and self-reported balance confidence will be measured with the FES-I.",[27,215,29,35,28],[291,292,293,294,295],"Balance assessment","Functional test","Parkinson disease","Postural stability","Risk of falls","2025-08-28",{"date":298,"type":43},"2025-08-29",{"date":300,"type":43},"2025-05-01",{"date":302,"type":21},"2025-08-30",{"name":49,"class":50}]